United States
Alonzo Mourning was at the height of his legendary basketball career when he was diagnosed with what is now known as APOL1-mediated kidney disease (AMKD). We’re teaming up to help raise awareness of AMKD and empower others to take a proactive role in their health. (Alonzo Mourning is a paid spokesperson for Vertex Pharmaceuticals.)
The Sickle Cell Disease Partnership is a multistakeholder coalition, launched in June, which works to improve care and access for people living with sickle cell disease. Here, Chief Patient Officer Amit Sachdev discusses the partnership, its goals and the reasons it was founded.
Jonathan has deep legal, industry and business experience and expertise that will support our continued growth. He joined Vertex in 2022 and serves on the Executive Committee and oversees all aspects of our global legal and compliance functions.
Her earned his bachelor’s degree in history from Brown University and his law degree from Yale Law School. Prior to Vertex, Jonathan served in several executive roles at Agios Pharmaceuticals, including Chief Legal Officer and most recently Chief Financial Officer and Head of Corporate Affairs. Prior to this, he served as Executive Vice President, General Counsel at Celgene, where he was responsible for its global legal function, and before that as Senior Vice President, Tax and Treasury. Prior to Celgene, he served in various leadership roles at Bunge Limited and Alcon, Inc. He began his legal career at Hopkins & Sutter, rising to the level of partner, and was also partner at Foley & Lardner after the firms merged.
Jonathan has deep legal, industry and business experience and expertise that will support our continued growth. He joined Vertex in 2022 and serves on the Executive Committee and oversees all aspects of our global legal and compliance functions.
Her earned his bachelor’s degree in history from Brown University and his law degree from Yale Law School. Prior to Vertex, Jonathan served in several executive roles at Agios Pharmaceuticals, including Chief Legal Officer and most recently Chief Financial Officer and Head of Corporate Affairs. Prior to this, he served as Executive Vice President, General Counsel at Celgene, where he was responsible for its global legal function, and before that as Senior Vice President, Tax and Treasury. Prior to Celgene, he served in various leadership roles at Bunge Limited and Alcon, Inc. He began his legal career at Hopkins & Sutter, rising to the level of partner, and was also partner at Foley & Lardner after the firms merged.
Mr. Upadhyay joined our Board in 2022. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, a position he has held since July 2019. Prior to joining Zimmer Biomet, Mr. Upadhyay served as Senior Vice President, Global Financial Operations, at Bristol Myers Squibb (BMS) from November 2016 until June 2019, where he was responsible for strategic and operational initiatives across BMS’s supply chain, commercial operations, R&D and business development. Prior to that, he served as Executive Vice President and Chief Financial Officer of Endo International and as an executive in various global finance and strategy leadership roles at BD (Becton, Dickinson and Company) including Interim Chief Financial Officer, Chief Accounting Officer and CFO of International. In addition, Mr. Upadhyay has also held several global finance and strategy roles at AstraZeneca and Johnson & Johnson, including R&D, supply chain, commercial operations and business development. Mr. Upadhyay spent the early part of his career in public accounting with KPMG, earning his CPA and CMA designations. He also currently serves as a member of the board of directors for CSC (Corporate Services Company), a privately held business solutions company. Mr. Upadhyay holds a Bachelor of Science in finance from Albright College and an M.B.A. from The Fuqua School of Business at Duke University.
Mr. Upadhyay joined our Board in 2022. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, a position he has held since July 2019. Prior to joining Zimmer Biomet, Mr. Upadhyay served as Senior Vice President, Global Financial Operations, at Bristol Myers Squibb (BMS) from November 2016 until June 2019, where he was responsible for strategic and operational initiatives across BMS’s supply chain, commercial operations, R&D and business development. Prior to that, he served as Executive Vice President and Chief Financial Officer of Endo International and as an executive in various global finance and strategy leadership roles at BD (Becton, Dickinson and Company) including Interim Chief Financial Officer, Chief Accounting Officer and CFO of International. In addition, Mr. Upadhyay has also held several global finance and strategy roles at AstraZeneca and Johnson & Johnson, including R&D, supply chain, commercial operations and business development. Mr. Upadhyay spent the early part of his career in public accounting with KPMG, earning his CPA and CMA designations. He also currently serves as a member of the board of directors for CSC (Corporate Services Company), a privately held business solutions company. Mr. Upadhyay holds a Bachelor of Science in finance from Albright College and an M.B.A. from The Fuqua School of Business at Duke University.
Incredible talent and cross-functional collaboration. All that and more with Vertex’s type 1 diabetes team. Meet a few of the team members who are making a difference.
Guided by our uncompromising commitment to patients, we are committed to going the distance in cystic fibrosis. Learn more about what we're focused on as we continue our journey.
Sustainability is both a priority and a team effort. Learn more about how we're dedicated to being responsible global citizens from Executive Director Katharine Jensen.